CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗中的代谢挑战与干预
英文原题：Metabolic challenges and interventions in CAR T cell therapy.
查看英文原题
Metabolic challenges and interventions in CAR T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 已在血液肿瘤中取得临床成功，成为癌症治疗新支柱，但实体瘤临床疗效尚难以重复验证。本综述分析肿瘤微环境中的代谢压力与信号，如何通过CAR-T 内在反应决定因素和外部障碍限制疗效。作者还讨论CAR-T 制造中靶向并重塑代谢程序的新方法，最后总结旨在提高CAR-T 代谢适应性、增强其抗肿瘤效应及在肿瘤微环境中存活能力的策略。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cells have achieved true clinical success in treating hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of cancer therapy. Although these promising effects have generated strong interest in expanding the treatment of CAR T cells to solid tumors, reproducible demonstration of clinical efficacy in the setting of solid tumors has remained challenging to date.
Here, we review how metabolic stress and signaling in the tumor microenvironment, including intrinsic determinants of response to CAR T cell therapy and extrinsic obstacles, restrict the efficacy of CAR T cell therapy in cancer treatment.
In addition, we discuss the use of novel approaches to target and rewire metabolic programming for CAR T cell manufacturing. Last, we summarize strategies that aim to improve the metabolic adaptability of CAR T cells to enhance their potency in mounting antitumor responses and survival within the tumor microenvironment.
论文信息
- 作者
- Peng JJ、Wang L、Li Z、Ku CL、Ho PC
- 单位
- Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.Switzerland
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Science immunology2023 Apr 14
- 原文标识
- PubMed 37058548 · DOI 10.1126/sciimmunol.abq3016